The Latest Breaking News from FDA

The upcoming ruling could curtail access to what is most commonly referred to as the abortion pill.

The Court granted two petitions for certiorari seeking review of a controversial lower court decision limiting federal approval of mifepristone.

Case will determine future of mifepristone in first major abortion issue to reach country’s highest court since it overturned Roe

The court's action sets up a collision between the Food and Drug Administration's 23-year study and supervision of mifepristone, and the circumstances under which it can be prescribed.

The Supreme Court has agreed to take up a dispute over a medication used in the most common method of abortion in the United States

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The case is the first major Supreme Court abortion case since the landmark Dobbs v. Jackson Women’s Health Organization decision last year.

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

The stock slumped hard in the past week.